Pharma Exclusives Pressreleases
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
Wednesday, July 30, 2025Dr Falk Pharma GmbH a researchbased pharmaceutical company specializing in digestive and metabolic medicine Allianthera Suzhou Biopharmaceuticals Co Ltd and its affiliate Allianthera Boston Inc
Touchlight Introduces mbDNA™: A “Best-In-Class" Circular Single Stranded DNA (ssDNA) Platform Enabling Superior Gene Editing
Wednesday, July 30, 2025Touchlight a pioneer in cellfree DNA innovation is proud to announce the commercial launch of their new technology for nonviral gene editing mbDNA megabulb DNA Its novel circular singlestranded DNA ssDNA
Ofichem expands drug substance capabilities with acquisition of Meribel Pharma Solutions’ Uppsala site in Sweden
Tuesday, July 29, 2025Ofichem a European CDMO specialising in highquality active pharmaceutical ingredients APIs and integrated drug development and manufacturing services today announced the acquisition of Meribel Pharma Solutions site in Uppsala Sweden
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
Friday, July 25, 2025Novo Nordisk today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion recommending an update of the Alhemo concizumab
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
Friday, July 25, 2025Rocheannounced today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA issued a negative opinion on the conditional marketing authorisation CMA for Elevidys
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease
Wednesday, July 23, 2025Roche announced today it has received CE Mark for its Elecsys pTau test to measure phosphorylated Tau pTau protein which is an indicator of amyloid pathology a hallmark of Alzheimers disease
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
Wednesday, July 23, 2025Rocheannounced today that the European Commission has approved Itovebi inavolisib in combination with palbociclib Ibrance and fulvestrant for the treatment of adult patients with PIKCAmutated oestrogen receptor
Roche provides update on astegolimab in chronic obstructive pulmonary disease
Monday, July 21, 2025Rocheannounced today topline results from the pivotal phase IIb ALIENTO n and the phase III ARNASA n trials investigating astegolimab compared to placebo on top of standard of care maintenance therapy
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Thursday, July 17, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative nextgeneration treatment options today announced that it has received approval
U.S. FDA Approves Finerenone for New Indication in Patients with Heart Failure with Left Ventricular Ejection Fraction of 40%
Monday, July 14, 2025Finerenone is the first drug targeting the mineralocorticoid receptor MR pathway to demonstrate statistically significant and clinically meaningful cardiovascular benefits in a Phase III study in adult patients with heart failure
